CN1053825C - Wuling C-hepatitis powder - Google Patents
Wuling C-hepatitis powder Download PDFInfo
- Publication number
- CN1053825C CN1053825C CN95115623A CN95115623A CN1053825C CN 1053825 C CN1053825 C CN 1053825C CN 95115623 A CN95115623 A CN 95115623A CN 95115623 A CN95115623 A CN 95115623A CN 1053825 C CN1053825 C CN 1053825C
- Authority
- CN
- China
- Prior art keywords
- radix
- hepatitis
- powder
- viruses
- rhizoma rhei
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to Wu ling hepatitis C powder which is composed of raw materials of the following weight percentage: 6 to 7 of Chinese magnolivine fruit, 6 to 7 of tuckahoe, 9.5 to 10.5 of ophiopogon, 6 to 7 of herba artemisiae, 6 to 7 of bupleurum root, 9.5 to 10.5 of radix glycyrrhiza, 9.5 to 10.5 of common selfheal fruit-spike, 6 to 7 of gentian, 12 to 13 of white peony alba, 7.5 to 8.5 of red sage root, 1.5 to 2.5 of charred Radix et Rhizoma Rhei and 14.5 to 15.5 of oldenlandia. A Chinese patent medicine of the present invention has the pharmacologic effect on the prevention of hepatitis C viruses, has the efficiency of darkening the antibody of the viruses, and has the functions of reducing enzymes, enhancing immunological functions and dispersing stagnated liver qi for relieving qi stagnation. The effective rate is 93.3%, and the darkening rate is 66.7%.
Description
Wuling C-hepatitis powder belongs to Chinese patent medicine.
The Chinese patent medicine of treatment hepatitis belongs to symptomatic treatment at present, and its clinical effectiveness is not good, and the antiviral drugs of high specificity, the function of do not possess the protection liver function again, regulating immunity of organism, transaminase lowering.
The objective of the invention is to develop a kind of have anti-hepatitis C virus RNA viruses, raising hepatitis C negative conversion rate, the liver protecting function, mould, the enhancing human body immunity function of recovery commentaries on classics ammonia, clinical Chinese patent medicine with Wuling C-hepatitis powder of Comprehensive Treatment hepatitis C.
The present invention is made up of Fructus Schisandrae Chinensis, Poria, Radix Ophiopogonis, Herba Artemisiae Scopariae, Radix Bupleuri, Radix Glycyrrhizae, Spica Prunellae, Radix Gentianae, the Radix Paeoniae Alba, Radix Salviae Miltiorrhizae, charred Radix Et Rhizoma Rhei, Herba Hedyotidis Diffusae.They respectively account for by weight percentage: Fructus Schisandrae Chinensis 6～7, Poria 6～7, Radix Ophiopogonis 9.5～10.5, Herba Artemisiae Scopariae 6～7, Radix Bupleuri 6～7, Radix Glycyrrhizae 9.5～10.5, Spica Prunellae 9.5～11.5, Radix Gentianae 6～7, the Radix Paeoniae Alba 12～13, Radix Salviae Miltiorrhizae 7.5～8.5, charred Radix Et Rhizoma Rhei 1.5～2.5, Herba Hedyotidis Diffusae 14.5～15.5
Chinese patent medicine of the present invention has the pharmacology of anti-hepatitis C virus RNA, the effect that hepatitis C virus antibody is turned out cloudy.It also has the effect of falling mould, raise immunity, dispersing the stagnated live-QI to relieve the stagnation of QI.The effective percentage of taking this medicine treatment hepatitis C is 93.3%, and negative conversion rate is 88.7%, the advantage of non-relapse after healing.
Embodiment: select Fructus Schisandrae Chinensis 6.5, Poria 6.5, Radix Ophiopogonis 10, Herba Artemisiae Scopariae 6.5, Radix Bupleuri 6.5, Radix Glycyrrhizae 10, Spica Prunellae 10, Radix Gentianae 6.5, the Radix Paeoniae Alba 12.5, Radix Salviae Miltiorrhizae 8, charred Radix Et Rhizoma Rhei 2, Herba Hedyotidis Diffusae 15 by weight percentage.Above 12 flavor medicated powder are broken, cross sieve No. 5, again through cobalt
50Sterilize and got final product packing in 30 minutes.
Claims (1)
1, Wuling C-hepatitis powder, it is characterized in that it is made up of Fructus Schisandrae Chinensis, Poria, Radix Ophiopogonis, Herba Artemisiae Scopariae, Radix Bupleuri, Radix Glycyrrhizae, Spica Prunellae, Radix Gentianae, the Radix Paeoniae Alba, Radix Salviae Miltiorrhizae, charred Radix Et Rhizoma Rhei, Herba Hedyotidis Diffusae, they respectively account for by weight percentage: Fructus Schisandrae Chinensis 6～7, Poria 6～7, Radix Ophiopogonis 9.5～10.5, Herba Artemisiae Scopariae 6～7, Radix Bupleuri 6～7, Spica Prunellae 9.5～10.5, Radix Gentianae 6～7, the Radix Paeoniae Alba 12～13, Radix Salviae Miltiorrhizae 7.5～8.5, charred Radix Et Rhizoma Rhei 1.5～2.5, Herba Hedyotidis Diffusae 14.5～15.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95115623A CN1053825C (en) | 1995-09-15 | 1995-09-15 | Wuling C-hepatitis powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95115623A CN1053825C (en) | 1995-09-15 | 1995-09-15 | Wuling C-hepatitis powder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1145238A CN1145238A (en) | 1997-03-19 |
| CN1053825C true CN1053825C (en) | 2000-06-28 |
Family
ID=5080572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN95115623A Expired - Fee Related CN1053825C (en) | 1995-09-15 | 1995-09-15 | Wuling C-hepatitis powder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1053825C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7422760B2 (en) | 2004-02-19 | 2008-09-09 | Phynova Limited | Plant-based medicament for the treatment of Hepatitis C |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2428974B (en) * | 2005-08-12 | 2010-02-03 | Phynova Ltd | Further medical use of a botanical drug or dietary supplement |
| CN1899370B (en) * | 2006-07-01 | 2010-05-26 | 邓德刚 | Compound calyx melo extract tablet |
-
1995
- 1995-09-15 CN CN95115623A patent/CN1053825C/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| 江苏医药1990,16(9) 1990.1.1 张新年等，慢性活动性肝炎伴自身免疫的中西医结合治疗 * |
| 河北中医1994,16(5) 1994.1.1 王钧，虎白合剂治疗急性传染性黄疸型肝炎359例 * |
| 河北中医1994,16(5) 1994.1.1 王钧，虎白合剂治疗急性传染性黄疸型肝炎359例;江苏医药1990,16(9) 1990.1.1 张新年等，慢性活动性肝炎伴自身免疫的中西医结合治疗;陕西中医1990,11(5) 1991.1.1 愈肝汤治疗急性病毒性肝炎327例 * |
| 陕西中医1990,11(5) 1991.1.1 愈肝汤治疗急性病毒性肝炎327例 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7422760B2 (en) | 2004-02-19 | 2008-09-09 | Phynova Limited | Plant-based medicament for the treatment of Hepatitis C |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1145238A (en) | 1997-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101130005A (en) | Traditional Chinese medicine for treating blahs aypnia after hepatocerebral apoplexy | |
| CN1103223C (en) | Chinese medicine for treating cholecystitis | |
| CN1053825C (en) | Wuling C-hepatitis powder | |
| CN101062212A (en) | Chinese medicinal herb composition for treating gastritis | |
| CN1186687A (en) | Cancer preventing curing medicine series and its preparation | |
| CN1045387C (en) | "Sancao" medicine powder for hepatitis B | |
| CN1365819A (en) | Medicine for treating apoplexy | |
| CN1385191A (en) | Medicine for treating liver disease | |
| CN1331996A (en) | Hepatitis B treaitng pill | |
| CN101152540A (en) | Chinese traditional medicine for treating chronic hepatitis | |
| CN1136907C (en) | Making process of enzyme degrading oral liquid | |
| CN102813733A (en) | Herb tea capable of resisting cancer, preventing diabetes mellitus and enhancing immunity | |
| CN1224413C (en) | Chinese medicine granule preparation for curing stomatocace | |
| CN1223361C (en) | Decoction for positive reaction of hepatitis B transformation to negative | |
| CN1053815C (en) | Cundanzhengxin powder for viral myocarditis | |
| CN1130529A (en) | Aizikangfuning-Chinese patent drug for treating AIDS and preparing process thereof | |
| CN1086141C (en) | Medicine for treating early-stage hepatocirrhosis and its preparation | |
| CN101991762A (en) | Traditional Chinese medicine for treating refractory asthma and preparation method thereof | |
| CN1054767C (en) | Pharmaceutical preparation for treatment of leukoderma | |
| CN1282462C (en) | Medicine for treating variant viral hepatitis B | |
| CN1058622C (en) | Rehabilitation powder for hepatitis B | |
| CN1063062C (en) | Chinese herbal medicine preparation for curing cerebral thrombosis | |
| CN101229291B (en) | Chinese traditional medicine composition for treating virus hepatitis by immunoregulation | |
| CN101352496A (en) | Chinese medicine for treating hepatitis | |
| CN1059584C (en) | Pill for removing rheumatism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |